TWA
RPRX icon

TCI Wealth Advisors’s Royalty Pharma RPRX Stock Holding History

TCI Wealth Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-64
Closed -$2.31K – 1821
2023
Q1 		$2.31K Sell
64
-172
-73% -$6.38K ﹤0.01% 1933
2022
Q4 		$9.33K Buy
236
+155
+191% +$6.47K ﹤0.01% 1116
2022
Q3 		$3K Sell
81
-2
-2% -$85 ﹤0.01% 1829
2022
Q2 		$3K Buy
83
+32
+63% +$1.31K ﹤0.01% 1882
2022
Q1 		$2K Hold
51
– – ﹤0.01% 2019
2021
Q4 		$2K Buy
51
+5
+11% +$194 ﹤0.01% 2115
2021
Q3 		$2K Sell
46
-7
-13% -$272 ﹤0.01% 2171
2021
Q2 		$2K Buy
53
+5
+10% +$213 ﹤0.01% 2079
2021
Q1 		$2K Buy
48
+18
+60% +$853 ﹤0.01% 1873
2020
Q4 		$2K Buy
30
+19
+173% +$806 ﹤0.01% 1262
2020
Q3 		$0 Buy
+11
New +$472 ﹤0.01% 1644

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TCI Wealth Advisors's RPRX Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Royalty Pharma (RPRX) in Q2 2023, closing a stake of 64 shares — an estimated $2.31K sold.

TCI Wealth Advisors first reported a position in RPRX in Q3 2020 and held it in 11 quarters. The position peaked at $9.33K in Q4 2022. 325 funds tracked by Wall St. Rank hold RPRX as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Royalty Pharma position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 64 Royalty Pharma shares in Q2 2023, an estimated $2.31K.
  • TCI Wealth Advisors first reported a position in Royalty Pharma in Q3 2020 and held it in 11 quarters.
  • TCI Wealth Advisors's Royalty Pharma position peaked at $9.33K in Q4 2022.
  • 325 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.